Press coverage about AcelRx Pharmaceuticals (NASDAQ:ACRX) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AcelRx Pharmaceuticals earned a news impact score of 0.11 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 47.4047453571022 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- AcelRx Pharmaceuticals (ACRX) Expected to Post Earnings of -$0.24 Per Share (americanbankingnews.com)
- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) – Hot Stock under Review (nasdaqjournal.com)
- Guide to Trend Direction – AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) (stockspen.com)
- Lookout For Risk Factors – AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) (stocktradingpoint.com)
- AcelRx Pharmaceuticals, Inc. (ACRX) Stock is In Active Momentum on technical Analysis (investingbizz.com)
Separately, Zacks Investment Research cut AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $4.92.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Thursday, March 8th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.20). The firm had revenue of $0.74 million during the quarter, compared to analysts’ expectations of $2.90 million. sell-side analysts anticipate that AcelRx Pharmaceuticals will post -0.98 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/02/acelrx-pharmaceuticals-acrx-given-daily-news-impact-rating-of-0-11/2001931.html.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.